Hancock Jaffe Laboratories (NASDAQ:HJLI) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Insider and Institutional Ownership
0.9% of Hancock Jaffe Laboratories shares are owned by institutional investors. Comparatively, 91.4% of OraSure Technologies shares are owned by institutional investors. 1.7% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Hancock Jaffe Laboratories has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
This table compares Hancock Jaffe Laboratories and OraSure Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Hancock Jaffe Laboratories||-5,250.79%||-207.10%||-124.79%|
Earnings & Valuation
This table compares Hancock Jaffe Laboratories and OraSure Technologies’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Hancock Jaffe Laboratories||$190,000.00||91.50||-$13.04 million||($1.91)||-0.51|
|OraSure Technologies||$181.74 million||2.42||$20.40 million||$0.50||14.28|
OraSure Technologies has higher revenue and earnings than Hancock Jaffe Laboratories. Hancock Jaffe Laboratories is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Hancock Jaffe Laboratories and OraSure Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Hancock Jaffe Laboratories||0||0||1||0||3.00|
Hancock Jaffe Laboratories currently has a consensus target price of $3.00, suggesting a potential upside of 209.28%. OraSure Technologies has a consensus target price of $7.00, suggesting a potential downside of 1.96%. Given Hancock Jaffe Laboratories’ stronger consensus rating and higher possible upside, equities analysts plainly believe Hancock Jaffe Laboratories is more favorable than OraSure Technologies.
OraSure Technologies beats Hancock Jaffe Laboratories on 9 of the 14 factors compared between the two stocks.
About Hancock Jaffe Laboratories
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
About OraSure Technologies
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV?1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.